Valerio Therapeutics
ALVIO
Company Profile
Business description
Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.
Contact
49 Boulevard du General
Martial Valin
Paris75015
FRAT: +33 145587600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
38
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,704.40 | 143.20 | -1.82% |
| CAC 40 | 7,100.42 | 173.30 | 2.50% |
| DAX 40 | 20,280.26 | 490.64 | 2.48% |
| Dow JONES (US) | 37,615.47 | 2,930.46 | -7.23% |
| FTSE 100 | 7,910.53 | 144.45 | -1.79% |
| HKSE | 20,127.68 | 2,722.13 | -11.91% |
| NASDAQ | 15,254.01 | 1,296.60 | -7.83% |
| Nikkei 225 | 33,012.58 | 768.00 | -2.27% |
| NZX 50 Index | 11,837.18 | 54.26 | -0.46% |
| S&P 500 | 4,977.73 | 84.52 | -1.67% |
| S&P/ASX 200 | 7,510.00 | 157.80 | -2.06% |
| SSE Composite Index | 3,145.55 | 48.97 | 1.58% |